Table 3.
Acetate PET response assessment: clinical studies.
| Sample size | Outcome | |
|---|---|---|
| Renal cell cancer | ||
| Maleddu et al. (100) | 1 | [11C]acetate PET could predict response to sunitinib as early as 2 weeks after therapy initiation |
| Brain | ||
| Liu et al. (101) | 22 | [11C]acetate had a good sensitivity in detection, of meningioma compared to [18F]FDG. [11C]acetate performed better in monitoring five patients who had received gamma-knife surgery |
| Prostate | ||
| Yu et al. (98) | 6 | [11C]acetate PET scanning was highly accurate for determining the response to treatment in prostate cancer patients with bone metastases |
| Gomez et al. (99) | 19 | Changes in [11C]acetate may serve as a tool for monitoring radiation therapy response in high risk prostate cancer |
| Myeloma | ||
| Lin et al. (102) | 15 | Visual and quantitative analysis showed a higher detection rate of myeloma lesions at diagnosis than using [18F]FDG. After treatment, a 66% reduction in SUVmax was seen in patients with at least a very good partial response versus a 34% reduction in those with a PR. They concluded that [11C]acetate may be valuable for response assessment |